Transcatheter aortic valve implantation (TAVI) has been recently introduced as a means to treat patients with severe aortic valve stenosis at high risk or rejected for conventional surgery. In the present manuscript we summarize the Deutsches Herzzentrum Berlin (DHZB) experience with transapical TAVI starting from the initial steps for adequate TAVI team building and training and focusing on the technical issues and results in the fi rst 500 operated patients. We will also comment upon the future of TAVI in the light of the results from large recent multi-center trials.
Aortic valve stenosis (AVS) is the most common valvular cardiac pathology in Europe and North America. Its prevalence increases progressively with aging, and it presents as calcifi ed aortic stenosis in 2-7% of the population aged >65 years. 1 Surgical indications for aortic valve replacement (AVR) are well defi ned in the international guidelines where it is specifi ed that AVR should be performed only in symptomatic patients with severe AVS or in asymptomatic patients whenever there is an objective and subsequent left ventricular dysfunction. 1 Although the results of surgical AVR are satisfactory in both the perioperative and long term follow-up phases, the perioperative risks increase for elderly patients and for those with complex comorbid profi les, which includes the vast majority of patients referred for AVR. Moreover, many patients with severe symptomatic AVS are not referred to surgical treatment because the examining physician considers surgery too traumatic and a prohibitive mortality risk. 2 Conventional AVR requires full sternotomy, heart lung machine adoption, cardiac arrest (cardioplegia), and "openheart" replacement of the native aortic valve. Despite excellent results achieved by conventional AVR in the past, it is mandatory to consider alternative interventions for a less invasive procedure. In this context, trans-catheter aortic valve implantation (TAVI) was recently introduced to treat patients with severe AVS that were rejected or considered too high risk for conventional surgery. Ten years after the fi rst human implant, 3 TAVI is a well accepted technique for treatment of over 35.000 patients worldwide.
Multicenter prospective randomized trials recently demonstrated the superiority of TAVI over conventional medical therapy for management of those patients with severe AVS who were rejected for standard surgery. 4 In addition, TAVI is not inferior to conventional surgery for treatment of high risk surgical candidates (PARTNER trials). 5 The benefi ts of this innovative technique remain consistent even at mid-term follow-up. 6 We will summarize the Deutsches Herzzentrum Berlin (DHZB) experience with transapical TAVI starting from the establishment of DHZB TAVI team building and training principles in 2008 and moving towards the acquisition of a standardized patient selection and operative protocol. In the second part, we present results obtained with the fi rst 500 patients treated via this revolutionary surgical operation.
Building and training the TAVI team
Since the beginning of our experience with TAVI in 2008, the DHZB policy has been to structure two TAVI teams with complementary and synergic action: the core team and the virtual team. The core team consists of two anesthesiol-ogists with expertise in trans-esophageal echocardiography, fi ve surgeons from four different surgical generations and two experienced cardiologists. The virtual team consists of about 50 persons involved in the chain of treatment of TAVI patients from the beginning to the end of hospitalization and in the out-patient follow-up.
A computer simulator, training by dry runs, and visiting centers that performed procedural life-case demonstrations provided procedural preparation. After these early theoretical stages, a fi rst phase of proctoring was mandatory for the initial phases of the program building. External proctoring for the fi rst cases was applied by pioneering experts, depending on the type of TAVI procedure. 3, 7 This proctoring was continued by occasional and repeated visits by other experts in order to exchange experience, improve details of the procedure and identify possible systemic errors inherent within the TAVI process.
After external proctoring stages, internal proctoring was managed as a self-appraisal relationship with regard to surgical experience between the team members, where opinions were exchanged in an open discussion during evaluation of the TAVI processes. This internal proctoring involved the most experienced surgeon/cardiologist ("senior proctors"); it was then gradually taken over by other members of the team ("younger proctors"), according to their surgical experience. This allowed those who were taught to "be proctor and proctored." During the initial phase, senior proctors performed all procedures if possible complications were expected due to patients' clinical condition (e.g. poor LVEF, cardiogenic shock, age ≥ 90 years, special situations).
Dhzb clinical and procedural policies for TAVI patients selection and procedural planning
Inclusion Criteria. As previously emphasized, TAVI is proposed as a novel form of treatment for patients rejected from or at prohibitive risk for conventional aortic surgery to correct symptomatically severe AVS. Since the beginning of our experience at DHZB we have applied a "no exclusion" policy for referring patients to TAVI.
In fact, our idea is that every high-risk patient, including those with poor left ventricular ejection fraction (LVEF =10-20%) or cardiogenic shock or those requiring a rescue procedure, should be considered for TAVI; exceptions would be those with endocarditis or too large annuli. No patient should be refused because of co-morbidities.
Patients are evaluated and accepted for TAVI according to contemporary accepted criteria that emphasize the importance of a predicted high mortality score (Euro-SCORE >20%, STS-score>10%). We believe that an institutional evaluation should be performed on the basis of the single center experience with conventional AVR and TAVI. Furthermore, some patients who do not fulfi ll the high risk classifi cation criteria may be accepted for TAVI for technical surgical reasons (e.g. porcelain aorta) or because of a high risk for conventional operation due to factors not covered by the risk scores (e.g. liver cirrhosis, malignancy, or in special situations such as in patients with assist devices).
The reason(s) must be widely acceptable and must be clearly formulated and documented. We consider only active or recent endocarditis to be an absolute contraindication for TAVI. Obviously, an annulus size exceeding the recommendations of the valve manufacturers would also preclude TAVI.
Valve Sizing and Prosthesis Selection. We have developed a standardized system for evaluating native AV annulus size that allows us to select the appropriate trans-catheter prosthesis. The aortic annulus is assessed by preoperative trans-thoracic echocardiography, multislice computed tomography and intra-operative trans-esophageal echocardiography. A two mm over-sized valve is generally used when adopting the Edwards SAPIEN valve (Edwards SA-PIEN THV, Edwards Lifesciences, Irvine, California). This device is the most frequently used trans-catheter aortic valve prosthesis at DHZB.
The Edwards SAPIEN heart-valve system consists of a trileafl et bovine pericardial valve and a balloon-expandable, stainless steel support frame ( Fig. 1 ). Generally, we choose a valve size of 23 mm for aortic valve annuli smaller than 21 mm, a 26-mm prosthesis for annuli between 21 mm and smaller than 24 mm, and a 29 mm valve for annuli between 24 mm and smaller than 27 mm. A native aortic annulus of 19 mm diameter is the lower limit orientation value for the 23-mm valve. In borderline cases, the decision is made on an individual basis, taking into account additional factors. These include: the distances from the annulus to the coronary artery ostia, the shape of the annulus (oval versus circular), the amount of material in the leafl ets, aortic diameters at the level of the sinuses of Valsalva, the sino-tubular junction, the ascending aorta, and the extent of calcifi cation in structures, such as the left ventricular outfl ow tract, anterior mitral leafl et, and aortic valve leafl ets themselves. 8
Intraoperative phases for transapical TAVI. Since the beginning of our experience, TAVIs have been done in our special operating room ( Fig. 2) that combines a catheter laboratory with all equipment and conditions necessary for surgery and sterile valve preparation before implantation; it includes requisite equipment for anesthesia, appropriate lighting, and a heart-lung machine. 8 All operations
are performed under general anesthesia with fl uoroscopy and echocardiography guidance.
The patient is placed in a supine position, and a small anterior thoracotomy is performed 2 to 3 cm below the left mammary groove. The left ventricular apex is more easily reached, and the procedure more comfortably performed, when the chest is entered at the 6 th or 7 th intercostal space. In this way, the amount of chest retraction and dissection can be reduced. In any case, the correct position of the left ventricular apex is previously evaluated by chest computed tomography, and the actual position of the apex is checked digitally by the operator from a small opening in the intercostal space before extending the thoracotomy. 8 Once the chest is entered, the pericardium is opened and the pericardial cradle is suspended to the thoracotomy cutaneous edges. At this stage, the left ventricular apex is identifi ed along with its anatomical boundaries ( Fig. 3) . Two polypropylene purse strings (either 3-0 or 2-0) are placed in an area of transaction between the left ventricular apex and the anterior wall of the left ventricle. The purse strings are reinforced with equine pericardium pledgets. At this stage a diagnostic pigtail is placed in the aortic root and pushed within the deepest aortic sinus to perform the fi rst aortography. The ideal radiographic projection is to have the nadirs of two aortic sinuses (normally the left and right sinuses) lined up. When all three sinuses are visible in the same projection, their nadirs should line up. This condition is usually achieved with a radiographic projection of around 15 degrees left anterior oblique and 15 degrees cranial. Once the ideal projection is achieved, heparin is administered (100 IU/kg of body weight) and the left ventricular apex is punctured with a needle. A guide-wire is then passed through the aortic valve under fl uoroscopy and echocardiography guidance. A small bore introducer (14 F) is passed over the wire and through the valve. An exchange of the initial standard guide-wire is made with a stiff guide-wire protected by an angiography catheter. The valvuloplasty balloon is passed over the wire and through the calcifi ed valve. An aortic balloon valvuloplasty is then done under rapid ventricular pacing (160 BPM).
After balloon defl ation, the external pacing is discontinued and the small bore introducer removed. At this stage, a large bore (24-26 F) introducer is inserted into the apex over the stiff wire. The prosthetic valve, previously mounted on a balloon, is inserted in the large bore introducer and positioned within the native aortic valve annulus under fl uoroscopy guidance. 7, 8 Aortography at this stage allows the initial selection of the valve position. Once the proper starting position has been identifi ed, rapid ventricular pacing (160 BPM) is started. In this moment, while starting to slowly infl ate the balloon, injection of 10 or 20 mL of contrast medium through the pigtail catheter (pulled back from the sinus of Valsalva 2 to 3 cm distally into the middle part of the ascending aorta just above the sinotubular junction) allows visualization (Fig 4) . The balloon is initially expanded by about 30-40%. The valve usually opens at the left ventricular end fi rst. The position of the valve is corrected if necessary, and the balloon is further infl ated to about 60-70%. When the valve is 50-60% opened, fi ne correction of the valve position is still possible. The optimum positioning of the valve is obtained by precise alignment relative to the coronary artery ostia, native valve, and native aortic valve annulus. These structures are perfectly visible by this technique. 9 Finally, the balloon is completely infl ated, and the valve is deployed in the desired position ( Fig. 4) . At this stage, the balloon is defl ated, external pacing is discontinued, and the balloon is retracted into the transapical sheath. After controlling the correct position and function of the newly implanted valve with the last aortography ( Fig. 4) , the introducer together with the balloon-catheter and the super-stiff guide-wire are pulled back and the apical purse strings are tied up.
This slow and controlled release of the prosthesis is an original modifi cation of the procedure by the DHZB TAVI team. It has been published in the medical literature as the "Berlin Addition." 9
Special conditions
Use of femoro-femoral cardiopulmonary bypass (CPB). Our DHZB policy states that elective normothermic femoro-femoral CPB should be considered in patients with low LVEF (10-20%), cardiogenic shock or rescue procedure, as well as in patients with signifi cantly enlarged right ventricle (RV) with poor RVEF and severe pulmonary hypertension. [10] [11] [12] Prophylactic use of intra-aortic balloon pump (IABP). IABP should be considered in patients with poor LVEF (10-20%) and in patients in cardiogenic shock. [10] [11] [12] Simultaneous treatment of combined coronary artery disease (CAD). Simultaneous elective percutaneous coronary intervention (PCI), or coronary artery bypass grafting if PCI is not possible, is considered for patients with concomitant CAD. Only the most relevant coronary artery stenosis is treated. [13] [14] [15] [16] "Valve-in-valve" concept for degenerated biological valve prosthesis. This concept may be considered in high-risk patients as a therapeutic or a palliative approach. 17, 18 Combined atrioventricular valve pathology. Concomitant signifi cant functional atrioventricular valve pathology is not treated in combination with TAVI, but later on by conventional surgery if necessary. The exception is grade IV tricuspid valve regurgitation. 
Post-implant paravalvular leakage or transvalvular regurgitation. Aortic regurgitation after valve

mm as assessed by computed tomography). The balloon is only slightly infl ated, the valve deployment begins, and angiography is performed (A). Then the valve position is corrected by pushing the valve slightly forwards into the aorta before full deployment (B). Concomitant angiography enables excellent visualization of the important anatomic factors in the proximal ascending aorta throughout the valve deployment and immediately after the valve is in its defi nitive position (C, D, E). In this particular case of high risk for occlusion of the right coronary artery, the valve is positioned very precisely and slowly and deployment requires a second injection of the contrast medium into the ascending aorta (D). Fluoroscopic view without contrast medium (F). (From Pasic M, Dreysse S, Drews T, et al. Improved technique of transapical aortic valve implantation: "the
Epilogue
Since the fi rst procedure in 2002, 3 TAVI has become standardized, with over 35,000 implants performed all over the world. Our own results with transapical TAVI along with those from multicenter prospective randomized trials using transfemoral and transapical TAVI 4-6 clearly indicate an encouraging midterm outcome along with acceptable perioperative mortality and rate of complications.
Results from the PARTNER trial reveal similarly high mortality at 2 years with TAVI and with surgical aortic valve replacement. In fact, follow-up mortality and complications rates presumably relate to the complex comorbid profi le of elderly patients with symptomatic severe AVS. 6 Perioperative results may impact follow-up outcome independently. In this context, residual aortic valve regurgitation after TAVI has been underestimated in the past. Paravalvular regurgitation is a design limitation of transcatheter aortic valves. This problem is most often secondary to incomplete and heterogeneous circumferential apposition of the prosthesis within the native annulus.
Recent scientifi c evidence 6 supports our DHZB policy of not accepting residual aortic insuffi ciency greater than two. In fact, even mild paravalvular aortic regurgitation seems to be independently associated with increased late mortality. 6 Avoiding valve under sizing and employing a patient's tailored post-TAVI re-dilation of the released transcatheter prosthesis can prevent this problem.
The future of TAVI. The successful application of TAVI in high risk patients ensures that it will, in the future, be used to treat even those individuals with low perioperative risk for conventional aortic valve surgery. The extension of TAVI indications will be aimed at minimizing the invasiveness of the procedure so as to further reduce the length and complexity of postoperative care. The SURTAVI Trial will start soon to evaluate the safety and effi cacy of TAVI for treatment of symptomatic severe AS in subjects who are at intermediate risk for aortic valve surgery (STS mortality risk score ≥3% and ≤8%).
In conclusion, TAVI is a revolutionary technique that has already changed the standard treatment of severe AVS. It should be emphasized that TAVI in general, and transapical TAVI in particular, is a "temptingly easy procedure (…) with 1001 sequences." 8 Failure to respect one of the preoperative and/or perioperative steps may lead to abrupt catastrophe. Consistent results can be achieved and maintained in even the sickest patients, and the procedure can be eventually extended to a lower risk population through a systematic and structured TAVI training program.
